Ckd Bio (063160) - Net Assets

Latest as of December 2025: ₩127.04 Billion KRW ≈ $86.09 Million USD

Based on the latest financial reports, Ckd Bio (063160) has net assets worth ₩127.04 Billion KRW (≈ $86.09 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩299.87 Billion ≈ $203.22 Million USD) and total liabilities (₩172.83 Billion ≈ $117.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Ckd Bio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩127.04 Billion
% of Total Assets	42.36%
Annual Growth Rate	5.74%
5-Year Change	-21.34%
10-Year Change	-6.01%
Growth Volatility	15.91

Ckd Bio - Net Assets Trend (2008–2025)

This chart illustrates how Ckd Bio's net assets have evolved over time, based on quarterly financial data. Also explore how large is Ckd Bio's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Ckd Bio (2008–2025)

The table below shows the annual net assets of Ckd Bio from 2008 to 2025. For live valuation and market cap data, see 063160 market cap.

Year	Net Assets	Change
2025-12-31	₩127.04 Billion ≈ $86.09 Million	-3.03%
2024-12-31	₩131.01 Billion ≈ $88.78 Million	+6.49%
2023-12-31	₩123.02 Billion ≈ $83.37 Million	-16.76%
2022-12-31	₩147.80 Billion ≈ $100.16 Million	-8.48%
2021-12-31	₩161.49 Billion ≈ $109.44 Million	-4.30%
2020-12-31	₩168.75 Billion ≈ $114.36 Million	+6.49%
2019-12-31	₩158.46 Billion ≈ $107.39 Million	+7.31%
2018-12-31	₩147.66 Billion ≈ $100.07 Million	+3.95%
2017-12-31	₩142.05 Billion ≈ $96.26 Million	+5.09%
2016-12-31	₩135.16 Billion ≈ $91.60 Million	+6.11%
2015-12-31	₩127.38 Billion ≈ $86.32 Million	+4.54%
2014-12-31	₩121.85 Billion ≈ $82.57 Million	-1.64%
2013-12-31	₩123.87 Billion ≈ $83.95 Million	-0.22%
2012-12-31	₩124.15 Billion ≈ $84.13 Million	+4.32%
2011-12-31	₩119.00 Billion ≈ $80.65 Million	+56.30%
2010-12-31	₩76.14 Billion ≈ $51.60 Million	+18.83%
2009-12-31	₩64.08 Billion ≈ $43.42 Million	+30.36%
2008-12-31	₩49.15 Billion ≈ $33.31 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Ckd Bio's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 863.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	₩84.22 Billion	66.30%
Other Components	₩42.82 Billion	33.70%
Total Equity	₩127.04 Billion	100.00%

Ckd Bio Competitors by Market Cap

The table below lists competitors of Ckd Bio ranked by their market capitalization.

Company	Market Cap
GLOSTER LTD (BSE) NSE:GLOSTERLTD	$72.54 Million
MedFirst Healthcare Services lnc TWO:4175	$72.54 Million
Eureka Acquisition Corp Unit NASDAQ:EURKU	$72.60 Million
Invictus Energy Ltd AU:IVZ	$72.61 Million
SP Systems Co.Ltd KQ:317830	$72.51 Million
Man Zai Industrial Co Ltd TWO:4543	$72.50 Million
Metrofile JSE:MFL	$72.47 Million
Siebert Financial Corp NASDAQ:SIEB	$72.47 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ckd Bio's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 131,009,150,220 to 127,035,604,250, a change of -3,973,545,970 (-3.0%).
Net loss of 2,888,351,290 reduced equity.
Dividend payments of 548,595,900 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩-2.89 Billion	-2.27%
Dividends Paid	₩548.60 Million	-0.43%
Other Changes	₩-536.60 Million	-0.42%
Total Change	₩-	-3.03%

Book Value vs Market Value Analysis

This analysis compares Ckd Bio's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.84x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.74x to 0.84x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩26373.47	₩19510.00	x
2018-12-31	₩27416.15	₩19510.00	x
2019-12-31	₩30892.63	₩19510.00	x
2020-12-31	₩30759.97	₩19510.00	x
2021-12-31	₩29437.20	₩19510.00	x
2022-12-31	₩26941.40	₩19510.00	x
2023-12-31	₩22425.33	₩19510.00	x
2024-12-31	₩23880.81	₩19510.00	x
2025-12-31	₩23156.50	₩19510.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ckd Bio utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -2.27%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -1.80%
• Asset Turnover: 0.53x
• Equity Multiplier: 2.36x
Recent ROE (-2.27%) is below the historical average (4.51%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2008	17.78%	10.48%	0.88x	1.93x	₩3.82 Billion
2009	25.26%	15.19%	0.96x	1.74x	₩9.78 Billion
2010	18.88%	11.83%	1.03x	1.55x	₩6.76 Billion
2011	9.18%	9.88%	0.56x	1.67x	₩-979.76 Million
2012	5.72%	6.24%	0.61x	1.49x	₩-5.31 Billion
2013	1.34%	1.65%	0.57x	1.42x	₩-10.73 Billion
2014	-0.91%	-1.04%	0.64x	1.35x	₩-13.29 Billion
2015	5.22%	6.24%	0.63x	1.34x	₩-6.08 Billion
2016	6.98%	8.35%	0.62x	1.34x	₩-4.08 Billion
2017	5.64%	6.78%	0.66x	1.26x	₩-6.19 Billion
2018	5.39%	6.39%	0.67x	1.25x	₩-6.81 Billion
2019	7.74%	8.94%	0.59x	1.47x	₩-3.58 Billion
2020	3.68%	4.98%	0.44x	1.68x	₩-10.67 Billion
2021	-4.07%	-4.62%	0.48x	1.85x	₩-22.73 Billion
2022	-11.30%	-10.70%	0.50x	2.11x	₩-31.48 Billion
2023	-19.66%	-15.09%	0.55x	2.39x	₩-36.49 Billion
2024	6.64%	5.07%	0.60x	2.17x	₩-4.40 Billion
2025	-2.27%	-1.80%	0.53x	2.36x	₩-15.59 Billion

Industry Comparison

This section compares Ckd Bio's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $401,390,357,055
Average return on equity (ROE) among peers: 0.79%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Ckd Bio (063160)	₩127.04 Billion	17.78%	1.36x	$72.53 Million
Dongwha Pharm.Co.Ltd (000020)	$252.93 Billion	10.38%	0.28x	$113.83 Million
Yuhan Corp. (000100)	$407.93 Billion	10.79%	0.55x	$4.57 Billion
Yuhan Corp Preferred (000105)	$1.65 Trillion	2.42%	0.28x	$59.61 Million
Yuyu Pharma (000220)	$69.50 Billion	3.97%	0.28x	$46.55 Million
Yuyu Pharma Inc (000225)	$117.04 Billion	1.10%	0.32x	$17.67 Million
Yuyu Pharma Inc (000227)	$78.29 Billion	7.52%	0.42x	$42.93 Million
Ildong Holdings Co Ltd (000230)	$169.10 Billion	-60.53%	4.10x	$76.14 Million
Samil Pharm (000520)	$127.83 Billion	1.30%	1.90x	$127.90 Million
Donga Socio Holdings (000640)	$875.86 Billion	17.02%	0.60x	$427.15 Million
Jw Pharmac (001060)	$265.44 Billion	13.94%	1.43x	$476.78 Million

About Ckd Bio

KO:063160 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$72.53 Million

₩107.03 Billion KRW

Market Cap Rank

#20438 Global

#1192 in Korea

Share Price

₩19510.00

Change (1 day)

-0.61%

52-Week Range

₩18470.00 - ₩24500.00

All Time High

₩101057.67